Celldex Therapeutics, Inc. (CLDX) Total liabilities 2016–2025
Celldex Therapeutics, Inc. (CLDX) total liabilities at each fiscal year-end, per SEC filings.
$55.8MFY2025 · since FY2016: $117.9M → $55.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $55.8M | +23.1% |
| FY2024 | $45.3M | +24.4% |
| FY2023 | $36.5M | +37.4% |
| FY2022 | $26.5M | +5.4% |
| FY2021 | $25.2M | -4.9% |
| FY2020 | $26.5M | -8.4% |
| FY2019 | $28.9M | -9.0% |
| FY2018 | $31.7M | -59.9% |
| FY2017 | $79.3M | -32.8% |
| FY2016 | $117.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Net marginCLDX Gross profitCLDX Gross marginCLDX Operating incomeCLDX Operating marginCLDX Operating cash flowCLDX Free cash flowCLDX Capital expendituresCLDX Return on equityCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Shareholders’ equityCLDX overview →